More poor data make $1.6 billion look steep for ARMO

24 January 2020
lilly-location-big-1

Detailed results from the Phase III SEQUOIA trial of pegilodecakin make for disappointing reading.

Eli Lilly (NYSE: LLY) is testing the PEGylated interleukin (IL)-10 agent, together with chemo, as an option for people with metastatic pancreatic cancer in a later-line setting.

While results released in October 2019 showed the study missed its primary endpoint of overall survival (OS), more details show secondary goals of progression-free survival (PFS) and overall response rate (ORR) were also missed.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Biotechnology